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Abstract
Chronic obstructive pulmonary disease (COPD) guidelines suggest using inhaled 
corticosteroids (ICS) in patients with severe airﬂ ow limitation or those at high 
risk of exacerbations. This recommendation is based on evidence demonstrating 
that ICS, especially when prescribed in ﬁ xed-dose combinations (FDC) with long-
acting 2 agonists (LABA), improve quality of life (QoL), decrease exacerbations 
and hospitalisations, and have been associated with a trend towards a reduction 
in all-cause mortality. Audit shows that routine prescribing practice frequently 
uses inhaler therapies outside current guidelines recommendations; severe to very 
severe disease constitutes about 20% of all COPD patients, but up to 75% of COPD 
patients are prescribed an ICS, with signiﬁ cant numbers given ICS/LABA as ﬁ rst-
line maintenance therapy. The role of ICS in the treatment paradigm for COPD is 
changing, driven by the growing evidence of increased risk of pneumonia, and the 
introduction of a new class of FDC; LABA and long-acting muscarinic antagonists 
(LAMA), which simplify dual bronchodilation and present a plausible alternative 
therapy. As the evidence base for dual therapy bronchodilation expands, it is likely 
that maximal bronchodilation will move up the treatment algorithm and ICS reserved 
for those with more severe disease who are not controlled on dual therapy. This 
change has already manifested in local COPD algorithms, such as those at Tayside, 
and represents a signiﬁ cant change in recommended prescribing practice. This 
review reassesses the role of ICS in the shifting treatment paradigm, in the context 
of alternative treatment options that provide maximal bronchodilation.
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Abbreviations
COPD chronic obstructive pulmonary disease
FDC ﬁ xed-dose combinations
FEV1 forced expiratory volume in one second
GOLD Global Initiative for Chronic Obstructive Lung Disease
ICS inhaled corticosteroids
INSPIRE  Investigating New Standards for Prophylaxis in Reduction of
 Exacerbations
LABA long-acting beta agonist
LAMA long-acting muscarinic antagonist
MRC Medical Research Council
NICE National Institute for Health and Clinical Excellence
NNH number needed to harm
NNT number needed to treat
QoL quality of life
SABA short-acting β2-agonist
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SAMA short-acting muscarinic antagonist
SAL salmeterol
SFC salmeterol/ﬂ uticasone propionate
SGRQ St Georges Respiratory Questionnaire
TDI transition dyspnoea index
TORCH Towards a Revolution in COPD Health 
Introduction
Important changes in our perspective and understanding 
of chronic obstructive pulmonary disease (COPD) have 
led to marked improvements in the treatment approach 
(1). Disease management has moved beyond spiromet-
ric parameters to include patient centred outcomes 
such as dyspnoea and exacerbation frequency, which 
are recognised as important elements in the assessment 
of treatment eﬀ ectiveness, and there is acknowledgment 
of the importance of COPD phenotyping in optimising 
therapeutic options. In 2013, the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) issued an 
updated document detailing the classiﬁ cation and treat-
ment of COPD (1). 
GOLD recommends classifying patients into one 
of four risk groups (A-D) using a combination of 
spirometry, symptoms and risk of future exacerbations. 
Treatment algorithms were suggested for each group, 
however bronchodilator therapy has remained the cor-
nerstone of pharmacological  management in all groups. 
Indeed, long-acting muscarinic antagonists (LAMA) 
are a ﬁ rst-line treatment option for any but those with 
mildest disease. GOLD suggests considering the use 
of inhaled corticosteroids (ICS) in patients with severe 
airﬂ ow limitation or for those who are at high risk of 
exacerbations. Th is is based on evidence demonstrating 
that ICS, especially when prescribed in ﬁ xed-dose com-
binations (FDC) with long-acting β2 agonists (LABA), 
improve quality of life (QoL), decrease exacerbations, 
hospitalisations (2), and have been associated with a 
trend towards a reduction in all-cause mortality (3). 
Dual bronchodilation, through co-prescribing of LABA 
and LAMA, could be an alternative to ICS/LABA in 
certain COPD phenotypes. Also this approach could be 
used particularly in patients who remain symptomatic 
after LABA monotherapy, but who cannot tolerate or 
do not wish to take ICS. Th is concept, however, is not 
given the prominence it merits in the new GOLD, (1) or 
indeed other, guidance (1, 4).
Th e pivotal study which showed beneﬁ ts of ICS/
LABA, recruited participants with a forced expiratory 
volume in one second (FEV1) of less than 60% pre-
dicted (3). Th ere is no evidence supporting the thera-
peutic beneﬁ t of ICS/LABA in COPD patients with 
less severe airﬂ ow limitation, irrespective of exacerba-
tion history (5). Despite this, ICS prescribing patterns 
demonstrate far wider application in COPD phar-
macotherapy than recommended, with ICS/LABA a 
widely prescribed maintenance drug. Audit shows that 
routine prescribing practice frequently uses inhaled 
therapies outside current guideline recommendations; 
severe to very severe disease constitutes about 20% of 
all COPD patients, but up to 75% of COPD patients are 
prescribed an ICS, with signiﬁ cant numbers given ICS/
LABA as ﬁ rst-line drug (6). Th is prescribing pattern 
may reﬂ ect the familiarity of prescribing ICS/LABA 
including historical prescribing where drug therapy 
is maintained because of disease stability, but it may 
also be a manifestation of physician concerns over the 
accuracy of diagnosis of COPD versus asthma result-
ing in continued ICS/LABA use. 
Th e breadth of prescribing of ICS in COPD and lack 
of eﬃ  cacy data in individuals with a FEV1 > 60% high-
lights the need for the risk-beneﬁ t proﬁ le of ICS to be 
considered closely. ICS/LABA combinations are associ-
ated with a number of side eﬀ ects beyond the topical 
eﬀ ects of oral candidiasis and dysphonia, the most seri-
ous of which is an increased incidence of pneumonia 
(7). Randomised controlled trials and observational 
studies have persistently described the risk of pneumo-
nia associated with ICS use, especially with ﬂ uticasone 
(3, 8). It has been suggested that there is an intra-class 
diﬀ erence in ICS with respect to the risk of pneumo-
nia; however, this is not a consistent observation (9). In 
addition, recent clinical trial data has suggested that the 
pneumonia extends to a new ICS currently in develop-
ment (10, 11). 
Th e evidence base for the eﬃ  cacy and safety of dual 
bronchodilation has been limited until now (12). How-
ever the evidence for new LABA/LAMA FDC suggests 
a greater eﬃ  cacy than LABA or LAMA monotherapy 
(13). Th is greater eﬃ  cacy has been shown over a diverse 
range of clinically relevant outcomes, and identiﬁ es 
LABA/LAMA FDC as a potential new treatment option 
when trying to maximise symptom control and reduce 
exacerbations. Th is review reassesses the role of ICS in 
the shifting treatment paradigm, in the context of alter-
native treatment options that provide maximal bron-
chodilation. 
Review
Inhaled corticosteroids in chronic obstructive 
pulmonary disease
Th irty years ago, ICS were established as eﬀ ective treat-
ments to reduce morbidity and mortality in asthma 
patients (14). Th is success prompted research into its 
possible therapeutic role in COPD, although initial evi-
dence of eﬃ  cacy was limited. Th e randomised controlled 
trials of ICS in COPD which followed in the 1990’s had 
mixed results. Th ere was no improvement in the rate 
of decline in lung function or exacerbation frequency 
when compared with placebo in studies of 6 months 
to 3 years duration (5, 15–19). It was not until ISOLDE 
(20); the ﬁ rst large, long-term, randomised, double-
blind, placebo-controlled trial of ICS, that reduction in 
exacerbation rates and health care utilisation of ICS as 
therapy was described. From this point on, clinical trials 
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analyses (2, 26). Analysis of 55 primary studies totalling 
16,154 participants comparing any dose of any type 
of ICS with a placebo control in patients with COPD, 
showed long-term use of ICS signiﬁ cantly reduced the 
mean rate of exacerbations (generic inverse variance 
analysis: MD −0.26 exacerbations/patient/year, pooled 
means analysis: MD −0.19 exacerbations/patient/year)
(20). In a pooled analysis of 5601 participants from 
6  studies with predominantly poorly reversible, severe 
COPD, the use of ICS/LABA FDC signiﬁ cantly reduced 
exacerbation rates (rate-ratio 0.87, 95% CI 0.80 to 0.94) 
compared with ICS alone (26).
In terms of lung function and QoL, post-hoc analyses 
of TORCH reported an adjusted rate of decline in FEV1 of 
55 mL/year for placebo, 42 mL/year with FP or SAL, and 
for the combination of drugs a 39 mL per year decline, 
suggesting that treatment with ICS, LABA or the combi-
nation of two, can slow FEV1 decline (27). Th e Cochrane 
analysis reported a pooled diﬀ erence in rate of decline 
of post-bronchodilator FEV1 of 6.88 mL/year (95% CI 
1.80 to 11.96, 5 studies, 4823 participants) in favour of 
ICS (2). TORCH reported an improvement with SFC of 
3.0 units of the St Georges Respiratory Questionnaire 
(SGRQ) compared to baseline after 3 years of treatment 
(p < 0.001 vs. placebo), with an improvement of 1.8 units 
in the ﬂ uticasone group (p < 0.001 vs. placebo); the pla-
cebo group showed a deterioration of 0.2 units in the 
SGRQ. Th e eﬀ ect was largest in more severe COPD—an 
improvement in SGRQ of 5.9  units with combination 
therapy in stage 4, and 3.3 units with GOLD stage 3; in 
stage 2, the SGRQ improvement was less (2.3 units), but 
still signiﬁ cant (3). Despite these positive ﬁ ndings, the 
prescribing of ICS for COPD has remained a controver-
sial subject (28, 29)
Safety proﬁ le of ICS treatment
Th e side eﬀ ects of ICS treatment range from frequent 
unpleasant local side eﬀ ects, such as oral candidiasis 
and dysphonia (2), to less common ones, such as adre-
nal suppression (30), cataracts (31, 32), and pneumonia 
(3, 8, 32–35). Th e side eﬀ ect proﬁ le potentially extends 
to include osteoporotic fractures (2, 36) and increased 
 diabetes risk (37, 38).
Th e studies of osteoporosis and fracture risk include 
combinations of randomised controlled trials and 
observational studies, each of which employed diﬀ er-
ent deﬁ nitions and therefore should be interpreted with 
caution. Several meta-analyses have reported conﬂ ict-
ing results; Loke and colleagues found a modest but sta-
tistically signiﬁ cant increased likelihood of fractures in 
those treated with ICS (36); however, a Cochrane review 
reported that long-term studies which measured bone 
eﬀ ects generally showed no major eﬀ ect on fractures 
and bone mineral density over 3 years of follow-up (2). 
Systemic corticosteroids are known to increase dia-
betes risk, but the impact of ICS is less well character-
ised. A large population based study of 388,584 patients 
with respiratory disease found treatment with ICS was 
focused on assessing ICS/LABA combinations as well as 
ICS and LABA as monotherapy. 
TRISTAN was one of the ﬁ rst, large (N = 1465), dou-
ble-blind, randomised studies, which compared twice-
daily salmeterol/ﬂ uticasone propionate 50/500 μg (SFC) 
to salmeterol 50 μg (SAL), ﬂ uticasone propionate 500 
μg (FP) or placebo (21). Although the primary endpoint 
was pre-bronchodilator FEV1, the number of exacerba-
tions was an important secondary endpoint assessed 
at every clinic visit. All therapies improved lung func-
tion, symptoms, health status and reduced use of rescue 
medication and frequency of exacerbations compared 
to placebo; however combination therapy with SFC was 
more eﬀ ective than salmeterol alone. Th e treatment 
eﬀ ect was most pronounced in severe disease; those 
with a baseline FEV1 < 50% showed a 30% reduction 
in exacerbation frequency with SFC compared to pla-
cebo, whereas there was only a 10% reduction in those 
patients whose FEV1 > 50%. 
Th e seminal TORCH trial (Towards a Revolution 
in COPD Health) followed several years later; this ran-
domised 6112 patients to SFC (100/1000 μg/day), SAL 
(100 μg/day), FP (1000 μg/day) or placebo (3). All-cause 
mortality was the primary endpoint, with lung function, 
exacerbations and QoL reported over a period of 3 years. 
Th e SFC treatment group demonstrated, a 25% reduc-
tion in the annual rate of exacerbations (0.85 (95% CI, 
0.80 to 0.90)) compared to placebo (1.13 (95% CI, 1.07 to 
1.20)), with a number needed to treat (NNT) of four to 
prevent one exacerbation. At the same time, Kardos and 
colleagues compared SFC with SAL monotherapy in 994 
patients with severe COPD for around 4 years (22). Com-
bination therapy with SFC reduced the total number of 
exacerbations (334 vs. 464, p < 0.0001), the annual rate of 
moderate/severe exacerbations (0.92 vs. 1.4, correspond-
ing to a 35% decrease, p < 0.0001) and the mean time to 
ﬁ rst exacerbation (128 vs. 93 days, p < 0.0001) (22).
A signiﬁ cant limitation of the studies described 
above is that they recruited patients based at least in 
part on an arbitrary FEV1 cut oﬀ  rather than the under-
lying phenotype ie emphysema or chronic bronchitis; it 
is well established that ICS will have beneﬁ cial eﬀ ects in 
those with predominantly moderate degrees of airway 
obstruction and airway hyperresponsiveness or mod-
est reversibility of FEV1 (23). A lack of phenotyping is 
also present when it comes to exacerbations, many of 
the studies looking into the usefulness of ICS tend to 
simply group all exacerbations together, however this 
may limit a study’s power to demonstrate ICS eﬀ ective-
ness. COPD exacerbations can be very diﬀ erent: infec-
tive (viral and/or bacterial), eosinophilic predominant 
or pauci-inﬂ ammatory (24). Th ere is evidence that dif-
ferent treatments can be eﬀ ectively adopted to reduce 
diﬀ erent COPD exacerbations, for instance, ICS added 
to long-acting bronchodilators can be utilised eﬀ ectively 
to avoid eosinophilic exacerbations (25).
Summary evidence of the eﬀ ect of ICS on COPD 
exacerbations is provided from recent Cochrane meta-
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 associated with a 34% (RR 1.34 (95% CI 1.29–1.39)) 
increased risk of new onset diabetes (deﬁ ned by ini-
tiation of an oral hypoglycaemic agent), with the high-
est dose associated with the greatest risk (37). More 
recently, a retrospective study of administrative claims 
data from the Australian Government Department 
of Veterans’ Aﬀ airs of more than 18,000 patients with 
diabetes, found there to be an increased risk of diabetes-
related hospitalisations with the use of high-dose ICS 
(38). However, it is the increased risk of pneumonia 
which represents the greatest concern in regards to the 
use of ICS in COPD management. 
ICS and pneumonia risk
Patients with COPD are at an increased risk of pneumo-
nia due to the nature of the disease itself and risks may 
be further increased with ICS use. TORCH showed an 
increased rate of pneumonia among all patients receiving 
treatment containing ICS, with a two-fold higher rate of 
pneumonia compared with patients in the placebo arm 
(3), with a number-needed-to-harm (NNH) of 17 (33). A 
subsequent analysis of the TORCH data showed that the 
risk factors for ICS-associated pneumonia were increas-
ing age, worsening spirometry, a history of COPD exac-
erbations in the year prior to the study, worse Medical 
Research Council (MRC) dyspnoea scores and a low 
body mass index; thus not dissimilar to the usual risk 
factors for pneumonia (39). Th e subsequent INSPIRE 
study (Investigating New Standards for Prophylaxis 
in Reduction of Exacerbations) comparing salmeterol 
plus ﬂ uticasone propionate 50/500 μg twice daily with 
tiotropium 18 μg once daily, reported double the rate 
of pneumonia with SFC (8%) than with tiotropium (4%) 
(34). Th e evidence of a dose-response for pneumonia 
risk comes from a nested case-control study of 175,906 
patients, which found that the highest doses of ICS were 
associated with the highest rate-ratio for hospitalisation 
(rate-ratio of 2.25) (35). Summary evidence of the risk 
is provided by a Cochrane meta-analysis of 14 studies 
combining 11,794 patients, which reported moderate-
level evidence of an increased pneumonia risk (by 50%) 
with ICS/LABA combinations versus LABA alone; 
however, mortality was identical between the treatment 
groups (23). 
Randomised controlled studies of new agents cur-
rently in clinical development have also reported pneu-
monia. ILLUMINATE, a double-blind, double-dummy 
trial in 523 patients with GOLD stages II and III, 
without exacerbations in the previous year, compared 
once-daily LABA/LAMA FDC (QVA149 110/50 μg) 
or twice-daily SFC 50/500 μg for 26 weeks (40). Radio-
logically conﬁ rmed pneumonia was only reported in 
the SFC treatment group (four patients; 1·5%). A new 
ICS/LABA FDC, recently approved by the United States 
Food and Drug Administration (FDA) for the treatment 
of COPD—ﬂ uticasone furoate/vilanterol (FF/VI)—was 
assessed for exacerbation prevention in COPD patients 
with a history of exacerbations in two replicate, phase 
III randomised double-blind trials of 1622 patients (10). 
Th ree doses of ﬂ uticasone furoate were used (50  μg, 
100 μg, and 200 μg) in combination with vilanterol 25 μg. 
Pneumonia and fractures were reported more frequently 
with FF/VI than with vilanterol alone. Eight deaths 
from pneumonia in the FF/VI groups compared with 
none in the vilanterol only group prompted discussion 
highlighting that the safety of ICS in COPD is a serious 
problem (11). Th e study was not powered to look at 
diﬀ erences in pneumonia-speciﬁ c mortality and overall 
mortality was not signiﬁ cantly diﬀ erent between the two 
groups. Interpreting the excess pneumonic episodes is 
complicated by the fact that ICS/LABA use in COPD 
decreases the rate of exacerbations and hospitalisations 
in clinical studies, and that no pneumonia deaths 
were identiﬁ ed secondary to SFC in TORCH (39). 
Reassuringly, a study looking at the impact of ICS use on 
outcome in COPD patients admitted with pneumonia 
did not show an association with worse mortality or the 
development of complications (41).
It has been suggested that ICS type may inﬂ uence 
the risk, with some studies such as PATHOS suggesting 
that ﬂ uticasone carries a higher risk than others such 
as budesonide (8, 42). In this observational, retrospec-
tive cohort study, budesonide/formoterol or SFC were 
compared for pneumonia event rates, admission to 
hospital related to pneumonia, and mortality associated 
with pneumonia. SFC patients were signiﬁ cantly more 
likely to experience pneumonia and had a higher mor-
tality related to pneumonia than patients treated with 
budesonide/formoterol. Th e authors oﬀ ered plausible 
explanations for the observed diﬀ erence, suggesting that 
the known immunosuppressant potency of ﬂ uticasone 
(10-fold higher than that of budesonide with regard to 
ex vivo inhibition of human alveolar macrophage innate 
immune response to bacterial triggers) could explain the 
ﬁ ndings. It must be noted that this was an observational 
study and that other studies of budesonide and mometa-
sone in COPD have shown an increased rate of pneu-
monia associated with use of these agents (9, 43). Th e 
deﬁ nitive answer as to whether this phenomenon is a 
class eﬀ ect or one speciﬁ c to ﬂ uticasone remains unclear.
ICS prescribing patterns
ICS’s important but targeted role in COPD treatment 
is not reﬂ ected in prescribing patterns. In a large Ital-
ian study investigating whether pulmonologists follow 
GOLD recommendations when prescribing treatment 
for COPD, ICS alone and ICS/LABA combinations were 
over-prescribed in GOLD stages I and II, in patients 
without exacerbations in 40% and 64%, respectively. 
Overall, 62.1% of prescribing was not in keeping with 
GOLD recommendations (44). Similar ﬁ ndings were 
described in a French study, which found that more 
than half of all patients in GOLD class I and II were pre-
scribed ICS (45). 
Tayside Allergy and Respiratory Disease Informa-
tion System (TARDIS) is a structured management 
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Table 1. COPD treatment algorithm employed by NHS Tayside.
The algorithm recommends that a combined inhaled steroid and long-acting bronchodilator should be prescribed only if the patient has persistent breathlessness or 
repeated exacerbations despite optimal bronchodilator therapy (deﬁ ned in step 3 as LABA and LAMA co-prescribing, coloured blue) and should be discontinued if no 
beneﬁ t after 4 weeks
Symptoms Inhaled Medication1
Step 1 Breathlessness and exercise limitation SABA or SAMA as required
Step 2 Persistent breathlessness and/or repeated exacerbations SABA or SAMA as required
SABA as required 
+
Or
+
LABA
LAMA
Step 32 Persistent breathlessness and/or repeated exacerbations despite treatment at step 2 SABA as required + LABA + LAMA
Step 4 Persistent breathlessness and/or repeated exacerbations despite treatment at step 3 SABA as required + ICS/LABA + LAMA
ICS, inhaled corticosteroids; LABA, long-acting β2-agonist bronchodilator; LAMA, long-acting anti-cholinergic; SABA, short-acting β2-agonist bronchodilator; SAMA, short acting anti-cholinergic
1Consider administration via an MDI and spacer at each step when:
The inspiratory ﬂ ow rate is < 30 L/min.
Poor technique with dry powder device.
Recurrent candidiasis of the mouth or throat.
Medication is carer administered.
Unlikely to generate sufﬁ cient inspiratory ﬂ ow when exacerbating.
2Theophylline use.
Oral slow release theophylline (Uniphyllin® m/r tablets) may be useful after a trial of short-acting bronchodilators and long-acting bronchodilators, or in patients who are unable to use 
inhaled therapy. Monitoring plasma levels of theophylline is not routinely necessary in stable patients but may be warranted in certain circumstances, eg, a change in clinical status, where 
toxicity is suspected or during concomitant use of interacting drugs.
programme for patients with COPD (46). Patients are 
reviewed no less than once annually, and data on spi-
rometry, exacerbations, and prescriptions, along with 
other variables is collected and recorded. A TARDIS 
study into the safety of β-blockers in COPD oﬀ ered 
valuable insights into real life ICS prescribing patterns 
in Scotland. In this dataset of 5977 patients, the mean 
post-bronchodilator FEV1 in patients receiving ICS as 
monotherapy was 65.3% and 63.1% in those patients 
receiving ICS/LABA FDC (47). 
NICE (National Institute for Health and Clinical 
Excellence) COPD guideline recommend considering 
ICS/LABA FDC after short-acting β2 agonists (SABA) 
or short-acting muscarinic antagonists (SAMA) 
in patients with FEV1 < 50% predicted who have 
exacerbations or persistent breathlessness, and as 
a therapeutic option for those who have persistent 
exacerbations or breathlessness despite maintenance 
therapy with a LABA, irrespective of FEV1 (4). 
According to GOLD, ICS/LABA is appropriate for 
patients with GOLD FEV1 < 50% or in those at high risk 
of future exacerbations (1). 
Clearly, ICS/LABA remains a valuable treatment 
option for selected patients with severe COPD or fre-
quent exacerbations, however, phenotyping individuals 
to direct ICS therapy to those most likely to beneﬁ t is 
an important aim. As described above, COPD is a het-
erogeneous disease with clinically relevant phenotypes 
and these emerging phenotypes must be considered 
when planning therapeutic intervention. For example 
there is probably small beneﬁ t of prescribing high dose 
ICS to a COPD patient with predominant emphysema 
especially in the presence of relatively little airﬂ ow 
limitation while potentially exposing the individual to 
the risk of well recognized adverse side eﬀ ects while at 
the same time ICS may potentially be used beneﬁ cially 
albeit without strict licensing criteria in non-smokers 
or ex-smokers with a relatively preserved FEV1 but 
with symptoms secondary to recurrent eosinophilic 
COPD exacerbations. 
Despite this, the current possibility of guideline con-
cordant ICS prescription irrespective of FEV1 moves 
ahead of the evidence, as the proven beneﬁ t of ICS is 
restricted to those with more severe airﬂ ow restriction. 
Th is is sustained in the opinion of the Scottish Medi-
cines Consortium, which has restricted the license of 
ICS/LABA to individuals with a FEV1 <50% (48). With 
emerging data on LABA and LAMA co-prescribing, 
both as free agents and FDC, the recommendation to 
consider dual bronchodilation only if ICS prescribing 
is not appropriate, will need to be altered in future 
guidelines. Important questions for guideline develop-
ment groups to address will include establishing the 
role of dual bronchodilation in treatment algorithms in 
relation to ICS/LABA. Th is will involve only identify-
ing which patients are most likely to beneﬁ t from dual 
bronchodilation and also taking into account factors 
such as risk and impact of side eﬀ ects, symptoms and 
patient preference.
Subtle changes to the COPD guideline in Tayside 
were recently introduced to reﬂ ect current treatment 
options. ICS/LABA FDC are still recommended for per-
sistent breathlessness or repeated exacerbations despite 
bronchodilator therapy (see step 4 in Table 1) with the 
proviso that ICS/LABA should only be prescribed if 
there are persistent symptoms and/or exacerbations 
despite maximal bronchodilator therapy (deﬁ ned as 
co-prescribing of LABA and LAMA). In essence, LABA 
and LAMA co-prescribing has been ‘pulled up’ the 
treatment algorithm ahead of ICS/LABA, encourag-
ing prescribing of ICS in patients with the most severe 
 disease. 
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Combining LABA and LAMA in COPD
Th e rationale for co-prescribing of LABA and LAMA 
is clear; combining long-acting bronchodilators with 
distinct, complementary and possibly synergistic 
mechanisms of action, has the potential to maximise 
bronchodilator response. Muscarinic receptor antago-
nists inhibit bronchoconstriction by inhibiting the 
binding of acetylcholine to muscarinic receptors on 
airway smooth muscle. β2-agonists directly activate 
β2-adrenoreceptors, causing airway smooth muscle 
relaxation. Th erefore, by simultaneously addressing 
both mechanisms of bronchodilation, one can poten-
tially modulate against the inter-patient and intra-
patient variability in response to individual agents (49). 
Th is should lead to a bronchodilator response which 
would not otherwise be seen if one or other agent 
were prescribed alone. Clinical studies have shown this 
potentially synergistic eﬀ ect of co-prescribing, in which 
the combined treatment eﬀ ect of LABA and LAMA is 
greater, or longer-lasting than expected from single 
agent bronchodilation. Th is may relate to M3-receptor 
blockade by LAMA amplifying and prolonging LABA-
induced β2-adrenoreceptors activation (50), and pro-
vides mechanistic support for the potential of LABA 
and LAMA inhaled combinations.
At least 12 randomised clinical trials have set out to 
investigate clinical outcomes after LABA and LAMA 
co-prescribing (formoterol, arformoterol, or indacaterol 
co-prescribed with tiotropium)(51). Th e largest of 
these, INTRUST-1 and INTRUST-2 trials, randomised 
1134 and 1142 patients with moderate to severe COPD 
respectively, already receiving open-label tiotropium 
18 μg, to indacaterol 150 μg once-daily or placebo for 
12 weeks (52). Concurrent use of indacaterol plus tiotro-
pium provided superior bronchodilation compared 
with tiotropium alone, increasing the FEV1 AUC by 130 
and 120 mL, trough by 80 and 70 mL (p < 0.001) and 
trough IC by 130 and 100 mL (p < 0.01). Importantly, the 
adverse event (AE) proﬁ le was similar between treat-
ments except cough, which was more common in the 
LABA plus LAMA patients. Meta-analysis of eight ran-
domised trials of tiotropium plus formoterol, compared 
with tiotropium alone, including 1868 patients with 
stable COPD, found that treatment with tiotropium plus 
formoterol improved lung function (weighted mean 
diﬀ erence in FEV1 of 105 mL) and symptom scores 
(weighted mean diﬀ erence in transitional dyspnoea 
index (TDI) of 1.5). However, there was no signiﬁ cant 
reduction in exacerbations seen when compared to 
treatment with tiotropium alone (53). Th ere was a trend 
towards a decrease in adverse events, although this was 
not statistically signiﬁ cant.
LABA and LAMA ﬁ xed-dose combinations
Th e development of a LABA/LAMA FDC is a simple way 
of ensuring that medication burden is reduced (single 
inhaler vs. multiple inhalers) thus minimising the risk 
of non-compliance. Th e challenge in the development 
of FDC inhalers is ensuring the balance between drug 
eﬃ  cacy and side eﬀ ect proﬁ le. Th is includes determin-
ing the minimally eﬀ ective doses of LABA’s and LAMA’s 
in combination preparations, accepting that they may 
not be the same as in monotherapy preparations due to 
combination pharmacodynamics. 
A number of LABA/LAMA FDC are currently in 
clinical development (Table 2). One combination, 
known as QVA149 (Ultibro®, Novartis), a FDC of inda-
caterol (110 μg) and glycopyrronium (50 μg), is the ﬁ rst 
once-daily dual agent bronchodilators to be approved 
for clinical use in Europe. Th e FDC of a LAMA, 
umeclidinium (UMEC), and a LABA, vilanterol (VI) 
(62.5/25 μg), known as UMEC/VI (Anoro, GlaxoSmith-
Kline), was approved by the FDA in December 2013, by 
the EMA in May, 2014 and in Japan in July, 2014. In a 
recent study, the use of once-daily UMEC/VI FDC over 
24 weeks resulted in signiﬁ cant improvements of trough 
FEV1 when compared to placebo as well as monotherapy 
of the individual components (54).
In Phase II studies, QVA149 showed a fast onset 
of action with a statistically signiﬁ cant (p < 0.0001) 
increase in FEV1 over placebo, indacaterol (300 μg and 
600 μg) 5 minutes post-dose on day 1 and a signiﬁ cant 
(p < 0.05) increase in FEV1 over placebo, indacaterol 
(300 μg and 600 μg) at all time-points on day 1 (55). In a 
cardiovascular safety-orientated trial, QVA149 was well 
tolerated with an acceptable AE proﬁ le (56). 
Table 2. LABA/LAMA ﬁ xed-dose combinations in late-stage clinical development
Combination Development phase Company Pivotal trials
Indacaterol/glycopyrronium (QVA149) 110/50 μg approved (EU, Japan) Novartis IGNITE program 11 trials, 11,000 patients
Umeclidinium/vilanterol 62.5/25 μg approved (US, EU, Japan) GSK, Theravance Phase III program 7 trials, 6000 patients
Olodaterol/
tiotropium
5 /5 μg ﬁ led in EU, US Boehringer Ingelheim TOviTO program
Several trials, 5000 patients
Aclidinium/
formoterol
400/12 μg (bid)
Filed in EU
Almirall, Forest ACLIFORM (NCT01462942), AUGMENT 
(NCT01437397)
LAC-MD-32; LAC-MD-36
Formoterol/
glycopyrronium
Phase III AstraZeneca PINNACLE 1 (NCT01854645)
PINNACLE 2 (NCT01854658)
Safety extension (NCT01970878)
Published with license by Taylor & Francis
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QVA149 is being investigated in a large ongo-
ing, Phase III programme called IGNITE comprising 
11 studies of more than 10,000 patients. One trial (ILLU-
MINATE) compared QVA149 with SFC in 523 patients 
with no history of exacerbations within the preceding 
year in a double-blind, double-dummy, parallel-group 
design (40). QVA149 provided signiﬁ cantly better, 
clinically relevant improvements in lung function with 
a rapid onset of action; at 26 weeks, FEV1 AUC 0–12h was 
signiﬁ cantly higher with QVA149, with a treatment dif-
ference of 0·138 L (p < 0·0001 versus SFC) (see Figure 1). 
Signiﬁ cant improvements in TDI scores, with a treat-
ment diﬀ erence of 0.76 (p = 0.003 versus SFC), and 
reduced use of rescue medication was also seen with 
QVA149. Th e study design allowed insights into the 
impact of ICS withdrawal—at Week 26 patients who 
had been on ICS therapy at enrollment showed simi-
larly higher values for FEV1 with QVA149 compared 
with SFC to those who had not been on ICS treatment. 
Th is study supports the approach of using one or more 
bronchodilators for symptomatic COPD at low risk of 
exacerbation without ICS. 
Conclusion
Th e role of ICS in the treatment paradigm for COPD 
is changing. Th is is driven by the growing evidence of 
increased risk of pneumonia, and a new class of LABA/
LAMA FDC which simpliﬁ es dual bronchodilation, 
presenting a plausible alternative for some patients. As 
the evidence base for dual bronchodilation expands, 
it is likely that maximal bronchodilation will move up 
the treatment algorithm, with ICS reserved for those 
with more severe disease who are not controlled on 
dual therapy or where the clinical phenotype is known 
to receive therapeutic beneﬁ t. Th is change has already 
manifested in some COPD algorithms, such as those 
at Tayside, representing a signiﬁ cant change in recom-
mended prescribing practice. Co-prescribing of LABA 
and LAMA is utilised much less frequently than LAMA 
monotherapy, ICS/LABA combinations, and the triple 
combination of LAMA plus ICS/LABA in recent reviews 
of prescribing practice (12). 
Th e key issue is the balance of risk-beneﬁ t of ICS in 
individual patients; the risk of pneumonia versus the 
beneﬁ t of reduced exacerbations. With the availability 
of new FDC, dual bronchodilation can be prescribed 
without increasing the dose of the LABA or LAMA 
component, and delivered in a simple, once-daily dosing 
regimen as a single inhaler. Th e once-daily dosing may 
be quite important for COPD patients, with evidence 
suggesting that compliance and adherence to treat-
ment plans is historically poor, with COPD patients 
particularly vulnerable to treatment adherence lapses 
(57). However, further data of the equivalence of LABA/
LAMA with ICS/LABA in respect to exacerbation fre-
quency is required.
For those patients already receiving ICS, the key con-
cern is the risk of precipitating an exacerbation by ICS 
cessation, therefore careful review and individualised 
patient management is required. A patient’s response 
to treatment, their preference, the likely side eﬀ ects, 
the risk of exacerbation and ﬁ nancial cost implications 
require consideration. However for those patients with 
FEV1 > 50% without frequent exacerbations, it is likely 
that the risk-beneﬁ t is in favour of considering stopping 
ICS treatment. ICS withdrawal may be associated with 
worsening of COPD control so must be done carefully 
(58). For those patients with the most advanced disease, 
triple therapy will remain the preferred treatment. Th e 
optimal posology of triple drug treatment requires fur-
ther consideration, with the likely scenario of LABA/
LAMA FDC co-prescribed with an ICS in a single 
inhaler emerging as the preferred option. 
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Figure 1. Comparison of FEV1 for QVA149 versus ﬂ uticasone/salmeterol. The 
ILLUMINATE double-blind, randomised trial of 523 patients. The primary study 
endpoint was FEV1 AUC0–12 h at 26 weeks for QVA149 vs. salmeterol/ﬂ uticasone (40). 
At Week 26, FEV1 AUC0–12 h was signiﬁ cantly higher with QVA149 compared with 
ﬂ uticasone/salmeterol combination, with a signiﬁ cant and clinically meaningful 
treatment difference of 138 mL (95% CI 100–176; p < 0.0001). 
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